Drug Research
Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China
Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC). Under the agreement, Ascletis gained an...
Drug Research
Takeda signs Omontys injection supply contract with Fresenius
Takeda Pharmaceuticals America (TPA) has signed a contract to supply Omontys injection to Fresenius Medical Care North America and certain of its affiliates. Omontys (peginesatide) injection is a synthetic, pegylated, peptide-based erythropoiesis-stimulating agent (ESA)...
Drug Research
Boehringer, Eli Lilly to launch diabetes drug in India
Boehringer Ingelheim India and Eli Lilly India is set to launch Linagliptin (brand name trajenta) 5mg film-coated tablets, for Type 2 diabetes in adults, in India. Linagliptin, which is approved in the US, the...
Drug Research
BioBlocks, Full Spectrum to develop new small molecule therapeutics
Full Spectrum Genetics and BioBlocks have signed an agreement to find new Small Molecule Therapeutics for protein-protein interactions. As part of the agreement, Full Spectrum Genetics protein analysis and engineering platform, MapEng, and BioBlocks'...
Drug Research
Mylan receives FDA approval for generic Lipitor ANDA
Mylan Laboratories, formerly Matrix Laboratories, has gained final FDA approval for its abbreviated new drug application (ANDA) of Atorvastatin Calcium Tablets of strengths 10mg, 20mg, 40mg and 80mg. The company begins immediate shipment of...
Drug Research
Cellectricon introduces Cellaxess discovery platform
Cellectricon has launched a new Cellaxess elektra discovery platform for automated electric field manipulation of adherent cells. Developed in collaboration with pharma and biotechnology companies, the Cellaxess platform enables scalable field stimulation, compound delivery...
Drug Research
Aegis wins US patent for octreotide formulations
Aegis Therapeutics has received US patent covering pharmaceutical composition of octreotide. The octreotide formulations incorporate Aegis' Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection. The Intravail/ProTek...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read